WallStreetZenWallStreetZen

NASDAQ: GILD
Gilead Sciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for GILD

Based on 12 analysts offering 12 month price targets for Gilead Sciences Inc.
Min Forecast
$69.00-12.35%
Avg Forecast
$81.08+3%
Max Forecast
$105.00+33.38%

Should I buy or sell GILD stock?

Based on 12 analysts offering ratings for Gilead Sciences Inc.
Buy
Strong Buy
1 analysts 8.33%
Buy
3 analysts 25%
Hold
8 analysts 66.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their GILD stock forecasts and price targets.

GILD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-09-04
lockedlocked$00.00+00.00%2024-08-15
lockedlocked$00.00+00.00%2024-08-09
lockedlocked$00.00+00.00%2024-08-09
lockedlocked$00.00+00.00%2024-07-08
Baird
Top 15%
86
HoldMaintains$80.00+1.63%2024-06-20
Barclays
Top 10%
91
HoldMaintains$76.00-3.46%2024-04-29
TD Cowen
Bottom 5%
5
Strong BuyMaintains$85.00+7.98%2024-04-26
Morgan Stanley
Top 19%
82
HoldMaintains$78.00-0.91%2024-04-26
HSBC
Bottom 21%
21
HoldUpgrades$69.00-12.35%2024-04-24

1 of 2

Forecast return on equity

Is GILD forecast to generate an efficient return?
Company
55.21%
Industry
149%
Market
59.09%
GILD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GILD forecast to generate an efficient return on assets?
Company
18.84%
Industry
25.19%
GILD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GILD earnings per share forecast

What is GILD's earnings per share in the next 3 years based on estimates from 12 analysts?
Avg 1 year Forecast
$3.78+344.45%
Avg 2 year Forecast
$7.24+751.42%
Avg 3 year Forecast
$7.54+786.94%
GILD's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

GILD revenue forecast

What is GILD's revenue in the next 3 years based on estimates from 10 analysts?
Avg 1 year Forecast
$27.6B-0.63%
Avg 2 year Forecast
$27.9B+0.34%
Avg 3 year Forecast
$28.7B+3.26%
GILD's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GILD earnings growth forecast

How is GILD forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
112.72%
Industry
36.05%
Market
17.02%
GILD's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
GILD's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
GILD's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

GILD revenue growth forecast

How is GILD forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
0.97%
Industry
9.3%
Market
9.26%
GILD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GILD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GILD vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
GILD$78.72$81.08+3.00%Buy
BMY$48.70$48.00-1.44%Hold
GSK$43.67$50.00+14.50%Buy
SNY$57.73$60.00+3.93%Strong Buy
PFE$28.56$33.86+18.55%Buy
View Top General Drug Manufacturer Stocks

Gilead Sciences Stock Forecast FAQ

Is Gilead Sciences Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 12 Wall Street analysts covering (NASDAQ: GILD) stock is to Buy GILD stock.

Out of 12 analysts, 1 (8.33%) are recommending GILD as a Strong Buy, 3 (25%) are recommending GILD as a Buy, 8 (66.67%) are recommending GILD as a Hold, 0 (0%) are recommending GILD as a Sell, and 0 (0%) are recommending GILD as a Strong Sell.

If you're new to stock investing, here's how to buy Gilead Sciences stock.

What is GILD's earnings growth forecast for 2024-2026?

(NASDAQ: GILD) Gilead Sciences's forecast annual earnings growth rate of 112.72% is forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 36.05%, and it is also forecast to beat the US market's average forecast earnings growth rate of 17.02%.

Gilead Sciences's earnings in 2024 is $1,053,000,000.On average, 12 Wall Street analysts forecast GILD's earnings for 2024 to be $4,703,331,084, with the lowest GILD earnings forecast at $4,332,572,442, and the highest GILD earnings forecast at $4,905,268,799. On average, 13 Wall Street analysts forecast GILD's earnings for 2025 to be $9,010,132,189, with the lowest GILD earnings forecast at $8,553,095,596, and the highest GILD earnings forecast at $9,738,328,058.

In 2026, GILD is forecast to generate $9,385,995,299 in earnings, with the lowest earnings forecast at $9,051,092,429 and the highest earnings forecast at $10,196,111,646.

What is GILD's revenue growth forecast for 2024-2026?

(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 0.97% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 9.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.26%.

Gilead Sciences's revenue in 2024 is $27,805,000,000.On average, 10 Wall Street analysts forecast GILD's revenue for 2024 to be $34,400,428,479,778, with the lowest GILD revenue forecast at $33,672,018,472,964, and the highest GILD revenue forecast at $35,688,942,993,946. On average, 10 Wall Street analysts forecast GILD's revenue for 2025 to be $34,735,899,065,956, with the lowest GILD revenue forecast at $33,982,058,850,895, and the highest GILD revenue forecast at $35,660,308,176,083.

In 2026, GILD is forecast to generate $35,747,005,689,628 in revenue, with the lowest revenue forecast at $34,613,269,835,962 and the highest revenue forecast at $37,306,187,707,165.

What is GILD's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: GILD) forecast ROA is 18.84%, which is lower than the forecast US Drug Manufacturers - General industry average of 25.19%.

What is GILD's Price Target?

According to 12 Wall Street analysts that have issued a 1 year GILD price target, the average GILD price target is $81.08, with the highest GILD stock price forecast at $105.00 and the lowest GILD stock price forecast at $69.00.

On average, Wall Street analysts predict that Gilead Sciences's share price could reach $81.08 by Sep 4, 2025. The average Gilead Sciences stock price prediction forecasts a potential upside of 3% from the current GILD share price of $78.72.

What is GILD's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: GILD) Gilead Sciences's current Earnings Per Share (EPS) is $0.85. On average, analysts forecast that GILD's EPS will be $3.78 for 2024, with the lowest EPS forecast at $3.48, and the highest EPS forecast at $3.94. On average, analysts forecast that GILD's EPS will be $7.24 for 2025, with the lowest EPS forecast at $6.87, and the highest EPS forecast at $7.82. In 2026, GILD's EPS is forecast to hit $7.54 (min: $7.27, max: $8.19).

What is GILD's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: GILD) forecast ROE is 55.21%, which is considered strong.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.